Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aztreonam for inhalation plus intravenous Colistin versus standard dual intravenous therapy for acute exacerbations in cystic fibrosis
2016-002832-34Phase 4Completed
- Sponsor
- Liverpool Heart and Chest Hospital
- Start
- Oct 2016
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aztreonam in cystic fibrosis (CF) (2 arms), sponsored by Liverpool Heart and Chest Hospital. Primary endpoint: Change in FEV1 % predicted from Day 0. Started Oct 2016; status: completed.
02
Drugs
aztreonam
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2016-002832-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002832-34.